Study of Hypertensive Population Under Treatment With Micardis in Real Clinical Conditions With the Goal to Control the Early Morning BP Rise.
Latest Information Update: 07 Nov 2019
Price :
$35 *
At a glance
- Drugs Telmisartan (Primary) ; Telmisartan/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 04 Aug 2009 New trial record